报价延迟最少15分钟:2026/03/20 16:47 EDT
盘后时段
|
||||
|
3.69 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.69
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.53/-0.55
|
|
企业价值
415.86M
|
| 资产负债 |
|
每股账面净值
0.85
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
7.83M
|
|
每股收益
0.20
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
